Major signaling pathways and key mediators of macrophages in acute kidney injury (Review)

NING LI¹⁻⁴*, JIALE CHEN¹⁻²*, PENGTAO WANG⁵, HAOJUN FAN¹⁻³, SHIKE HOU¹⁻³ and YANHUA GONG¹⁻³

¹Institute of Disaster Medicine, Tianjin University, Tianjin 300072; ²State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin 300350; ³Tianjin Key Laboratory of Disaster Medicine Technology, Tianjin 300072; ⁴Wenzhou Safety (Emergency) Institute, Tianjin University, Wenzhou, Zhejiang 325000; ⁵Emergency Department, General Hospital of Tianjin Medical University, Tianjin 300070, P.R. China

Received November 26, 2020; Accepted March 17, 2021

DOI: 10.3892/mmr.2021.12094

Contents

1. Introduction
2. Signal transduction of macrophages in AKI
3. Macrophage-derived mediators in AKI
4. Macrophage-sensing mediators in AKI
5. Conclusions

1. Introduction

Trauma involves the regulation of immune homeostasis, the production and release of various damage-associated molecular patterns (DAMPs) and the activation of the innate immune system (1). The post-traumatic biological response is a complex physiological phenomenon involving multiple inflammatory and thrombotic mediators, including cytokines, chemokines, complement receptors, oxygen free radicals, inflammatory cells (neutrophils, monocytes and macrophages) and endothelial cells (2). Macrophages exist in mammalian tissues and have essential functions (3). Although its origin continues to be controversial, the embryonic origin of the vital tissue that resides in macrophages is now understood (4). Macrophages residing in the majority of tissues are long-lived cells derived from transient hematopoietic waves of erythro-myeloid progenitors that emerge in the yolk sac (5). Although macrophages were previously known for their properties of host defense and scavenging of apoptotic cells, it is increasingly recognized that macrophages play a variety of roles in tissue development,
homeostasis control and wound repair (6,7). Inflammatory monocytes recruited by different mechanisms and activated tissue-resident macrophages are critical regulatory cells of tissue repair, regeneration and fibrosis (8). Several of these functional features are essential for tissue injury and repair. These cells can not only aggravate tissue damage by generating reactive oxygen species and other toxic components, but also produce various growth factors, including VEGF-α and TGF-β, to promote cell proliferation and repair (9). In the early 1990s, a type of selectively activated macrophage (type M2) was identified, which was different from the classical activated inflammatory macrophage (type M1) (10). M2 macrophages are usually described by their anti-inflammatory and wound healing effects (11). Macrophages can affect the metabolic tissue and alter the metabolic pathways. This phenotypic transformation occurs in glucose and lipid metabolism (12). Macrophages are the principal participants of the immune response after tissue injury, and their phenotypes vary from pro-inflammatory (M1) to anti-inflammatory (M2) macrophages, which can promote wound healing and scar repair (13). In addition, macrophage polarization is a highly dynamic process that is easily modulated by its microenvironment (14). Furthermore, the reversibility of macrophage polarization also has an important therapeutic value, particularly in diseases caused by an M1/M2 imbalance (15).

Acute kidney injury (AKI) has become a global public health problem with high morbidity, and mortality rates, as well as high healthcare costs (16). AKI is a disease characterized by acutely decreased renal function, the etiology of which can be multifactorial and is associated with complex pathophysiological mechanisms (17). AKI has been associated with mortality after traumatic war injuries (18). The pathogenesis of AKI varies with different types of damage. In ischemia/reperfusion (I/R)-induced AKI (I/R-AKI), the loss of the brush border of renal tubular epithelial cells (RTECs) and cell polarization leads to tubular obstruction, cell necrosis and apoptosis (19). In cisplatin-induced AKI, cisplatin causes DNA damage and mitochondrial damage, leading to inflammation and cell death (20). In contrast-induced AKI (CI-AKI), the formation of vacuoles, swelling of cells and oxidative stress lead to acute necrosis (21). In sepsis-induced AKI, sepsis may lead to renal vasodilation caused by inducible nitric oxide synthase release (19). Apart from kidney dialysis, there is no treatment for AKI that can reliably improve survival, reduce injury for AKI that can reliably improve survival, reduce injury for AKI that can reliably improve survival, reduce injury for AKI that can reliably improve survival, reduce injury (19). Apart from kidney dialysis, there is no treatment for AKI that can reliably improve survival, reduce injury (19). Apart from kidney dialysis, there is no treatment for AKI that can reliably improve survival, reduce injury (19). Apart from kidney dialysis, there is no treatment for AKI that can reliably improve survival, reduce injury (19). Apart from kidney dialysis, there is no treatment for AKI that can reliably improve survival, reduce injury. AKI participates in the regulation of immune system homeostasis, and numerous factors are involved, including erythropoietin (EPO), glycoprotein non-metastatic melanoma protein B (Gnmb), retinoic acid (RA), colony stimulating factor-1, myoglobin, dendritic cells, neutrophils and macrophages (23-25). A previous study demonstrated that macrophages are the principal effectors in AKI inflammatory responses (26). The dynamic roles and functional properties of macrophages in AKI are important for the identification of effective therapeutic targets (27). The activation and functional state of macrophages after renal injury are complex and diverse. Macrophages damage or repair renal tubules, and their role in interstitial fibrosis after renal injury varies with time and is determined by the type of renal injury (28). Due to the functional plasticity of macrophages (i.e., their ability to transform between the pro-inflammatory M1 and anti-inflammatory M2 phenotypes), macrophages play a complex role in the occurrence and development of AKI (29). Importantly, the polarization of macrophages may lead to the development of novel treatments to promote AKI repair (29). At present, it is considered that M2 macrophages and regulatory T cells are critical cells controlling inflammation, as well as tissue remodeling and repair following AKI (30). Previous studies have shown that M2 macrophage therapy can effectively reduce renal injury in AKI mice (31,32). The increase in M2 macrophages may play a pivotal role in the initial damage of human AKI and in the transition from AKI to chronic kidney disease (CKD) (33). Notably, animal experiments have shown that total or partial macrophage depletion in AKI may be beneficial to kidney damage (34). For example, M1 depletion has been demonstrated to have a universal protective effect on AKI; however, the results caused by M2 depletion are controversial (34). The latest research shows that nattokinase and hydrogen-rich solution produce a therapeutic effect on the inflammatory response of AKI by regulating the activity of macrophages (35,36). In summary, at present, the multifaceted role of macrophages in the occurrence and development of AKI remains open to further investigation.

2. Signal transduction of macrophages in AKI

Phosphatidylinositol-3 kinase (PI3K) signaling pathway. The PI3K pathway is one of the main signaling pathways that regulates macrophages, and it controls the critical switch between immune activation and inhibition in the process of inflammation (37). In addition, its contribution to macrophage polarization has gradually attracted the attention of numerous researchers, and been demonstrated to mediate the transformation of M2 macrophages (38,39). Certain studies have revealed that PI3Kγ plays a pivotal role in the polarization of macrophages and in the development of renal disease. Specifically, a lack of PI3Kγ leads to the polarization of M1 macrophages, resulting in an inflammatory environment (40,41). A previous study raised concerns regarding the inhibition of PI3K/AKT/mTOR in the treatment of AKI (41). Furthermore, previous studies found that aquaporin 1 (AQP1) can prevent renal tissue damage in AKI induced by bacterial lipopolysaccharide (LPS) by mediating the immune response. AQP1 alleviates sepsis-induced AKI by successfully activating PI3K, eventually leading to macrophage polarization to the M2 phenotype (Fig. 1) (42). Therefore, targeting PI3K-dependent M2 macrophage polarization may constitute a novel therapeutic approach to reducing sepsis-induced AKI.

Nuclear factor-κB (NF-κB) signaling pathway. NF-κB is a key regulator of inherent and adjustable immunity, which is closely linked to the pathogenesis of AKI (43). Previous studies have shown that pharmacological inhibitors (CLI-095 and pyrrolidine dithiocarbamate) of toll-like receptor 4 (TLR4)/NF-κB have a beneficial effect on rhabdomyolysis-induced AKI (RI-AKI) by controlling the production of pro-inflammatory cytokines and by regulating macrophage infiltration (44). Shu et al (45) found that LPS can...
upregulate the expression of CD38 in macrophages cultured in vitro in a time- and dose-dependent manner. Knocking down or blocking the expression of CD38 in macrophages inhibits the transduction of NF-κB signals, thereby reducing LPS-induced M1 polarization (45). It has been shown that quercetin may inhibit M1 polarization and NF-κB signal activation in the mouse kidney and spleen macrophages after LPS injection in a mouse model of AKI caused by LPS (45). Previous studies have reported that quercetin inhibits the expression of inflammatory components in macrophages both in vitro and in vivo, thus reducing renal injury (46,47). The mechanism is primarily associated with inhibition of the activity of macrophage-inducible C-type lectin (Mincle) and its downstream signal molecules Syk and NF-κB, whereby it regulates the polarization of macrophages by inhibiting pro-inflammatory M1 macrophages and activating anti-inflammatory M2 macrophages (48). Tan et al (49) have shown that curcumin treatment inhibits M1 macrophages in a Mincle-dependent manner, promoting the phenotypic transformation of macrophages from the M1 phenotype to the M2 phenotype and alleviating M1 macrophage-mediated kidney inflammation through a Syk/NF-κB-dependent mechanism. Hui et al (50) showed that Astragalus propinquus Schischkin and Panax notoginseng could control the activation of Mincle/Syk/NF-κB in vivo and in vitro. The mechanism may involve the inhibition of Mincle, which can decrease the activation of M1 macrophages and increase the activation of M2 macrophages. Zhou et al (51) demonstrated that recombinant human EPO exerts a regulatory effect on macrophages and a beneficial effect on the kidney by lowering the production of pro-inflammatory components via the TLR4/NF-κB signaling pathway in crush syndrome-induced AKI (Fig. 1). Therefore, EPO has a therapeutic potential for improving the prognosis of patients with AKI.

Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway. JAK is a non-receptor tyrosine kinase (52), while STAT molecules are potential nuclear transcription factors that are activated after recruitment of activated receptor complexes (53). The JAK/STAT signaling pathway transduces the downstream signals of a variety of cytokines, which is important in the pathogenesis of immune-related diseases (54). Previous studies have shown that EPO can assist M2 polarization through the JAK2/STAT3/STAT6 signaling pathway, suggesting the immunomodulatory ability of EPO in macrophage activation.
In addition, the cytokines interleukin (IL)-4 and IL-13 can activate the JAK3/STAT6 signaling pathway (Fig. 1). Deletion of IL-4 and IL-13 will lead to the decrease of the M2a phenotypic markers of tissue repair, which indicates that IL-4 and IL-13 play an essential role in the phenotypic polarization of M2a macrophages and are important in I/R-AKI recovery (56). Gpnmb is a transmembrane protein that negatively regulates macrophage inflammation (57). It has been observed that the IL-4/STAT6 signaling pathway participates in the process of M2 polarization by Gpnmb (24). This suggests that Gpnmb can be used as a biomarker to protect against AKI by regulating the polarization of macrophages (24).

3. Macrophage-derived mediators in AKI

**Macrophage migration inhibitory factor (MIF).** MIF is a crucial effector of the innate immune and inflammatory response (70,71). In contrast to the majority of cytokines, MIF is expressed by the epithelial lining of tissues in direct contact with the external environment as well as by immune and endocrine cells, which can improve the pro-inflammatory function of immune cells (72). MIF promoter polymorphism can predict the occurrence of postoperative AKI (73). A previous study demonstrated that MIF is increased in the urine of patients with acute pyelonephritis (APN), and that the concentration of MIF is associated with the severity of renal injury (74). Thus, MIF is considered to be a potential biomarker in patients with AKI caused by APN. AKI is the most common complication after cardiac surgery (75). It has been reported that MIF is a pressure-regulated cytokine that can protect the heart from myocardial I/R injury (76). MIF can limit the extent of necroptosing nephropathy and reduce oxidative stress effectively by regaining intracellular glutathione and reducing lipid peroxidation (77). MIF has clinical importance as treatment after cardiac surgery, as it may exert a potential nephroprotective effect in AKI (77). Thioredoxin-1 (TRX-1) is a MIF-regulatory protein with redox activity, and has a short residence time in blood (78). Long-acting TRX genetically fused with human serum albumin has the potential to treat RI-AKI by regulating oxidative stress and MIF (79).

Previous studies have found that MIF plays a pathogenic role in cisplatin-induced AKI, and MIF can mediate AKI via a CD74/NF-κB-dependent mechanism (Figs. 2 and 3) (80,81). The MIF inhibitor ribosomal protein S19, which targets MIF, may be a potential treatment strategy for AKI (82). Li et al (81) showed that high levels of MIF may be a pathogenic factor for I/R-AKI, and the level of MIF in plasma and urine may be associated with the progression and remission of AKI. Thus, targeting MIF may be a potential treatment for AKI (Table I).

**Macrophage CD163.** CD163 is a 130 kDa transmembrane receptor protein, which is mainly expressed by M2c macrophages (83). Urinary soluble CD163 (sCD163) may be used as a biomarker in certain renal inflammatory diseases (Fig. 2) (84). Sun et al (85) quantified sCD163 in the urine, and measured macrophage subtypes in the urine and renal biopsies (Table I). The authors found that urinary M1 is associated with interstitial M1 infiltration, while urinary sCD163 level and M2 subtype are positively correlated with infiltrating M2 in the glomeruli. The study by Sun et al (85) also revealed that urinary sCD163 has an improved diagnostic ability in distinguishing the disease etiology than that of traditional AKI urinary [Lipocalin-2 (Lcn-2)/neutrophil gelatinase-associated lipocalin (NGAL) and KIM-1], myeloid cell (CD11b) and pan-macrophage (CD68) markers. Rubio-Navarro et al (86) developed a targeted probe for CD163 by magnetic resonance imaging in vivo, thus confirming the presence of CD163-positive macrophages in human RI-AKI. Myoglobin activates early inflammatory M1 reaction and partial transformation to the M2 phenotype at a later stage, in which the high expression of CD163 is due to activation of heme oxygenase 1 and release of IL-10 (86). Furthermore, the aforementioned study developed gold-coated iron oxide nanoparticles with anti-CD163 antibody as a carrier,
which specifically targeted CD163 in the kidneys of mice injected with glycerol (86). Using probes targeting CD163 macrophages by magnetic resonance imaging could provide valuable information on the cellular composition of kidney lesions in rhabdomyolysis (86).

Lcn-2. Lcn-2/NGAL, is a member of the lipocalin family, which shares a tight tertiary structure, and ligand binding and post-translational modifications in Lcn-2 leads to diverse Lcn-2 functions (87). Lcn-2 is considered a therapeutic target for AKI, CKD and numerous types of cancer such as breast, esophagus and liver cancer (87-89). Lcn-2 plays a pivotal role in various kidney diseases, such as sepsis and IR (90). After renal injury, Lcn-2 increases rapidly in macrophages, and has highly stable iron binding and transport capacity (Fig. 2). A study by Urbschat et al (91) showed that mouse tubular epithelial cells (TECs) promoted the proliferation of epithelial cells by taking macrophage-derived iron-loaded Lcn-2. Mertens et al (92) concluded that the cellular source of Lcn-2 (TECs or macrophages) and its iron loading determine the biological function of Lcn-2 in cecal ligation and puncture (CLP)-induced kidney injury. At 24 h after CLP-induced kidney injury, elevated levels of iron-free Lcn-2 in TECs are primarily considered as markers of kidney injury, whereas elevated levels of iron-loaded Lcn-2 from macrophage sources are associated with markers of recovery (92) (Fig. 2; Table I). In summary, Lcn-2 is involved in renal injury and renal function recovery.

Macrophage extracellular traps (METs). ETs were first identified and described at neutrophils in 2004 (93). Neutrophil ETs (NETs) are generated by neutrophils after releasing granulin and chromatin, which together form extracellular fibers that bind gram-positive and negative bacteria. Similar to NETs, it has been found that a variety of pathogens and chemical stimulants can induce macrophages to produce METs, including gram-positive and -negative bacteria, acid-resistant bacteria, parasites, fungi, and chemical inducers and inhibitors (94). NETs and METs are the main drivers of the self-amplification circuit of necrotizing inflammation (Fig. 2) (95). A recent study reported the mechanism of muscle damage leading to renal dysfunction, and identified the formation of METs as a novel type of pathogenic driver and a potential therapeutic target (96). A previous study also found that macrophages participate in the pathological process of AKI caused by rhabdomyolysis (23). Macrophages release METs containing DNA fibers and granular proteins in a mouse model of rhabdomyolysis. During rhabdomyolysis, platelets activated by heme released by necrotizing muscle cells increased MET production by increasing intracellular
Figure 3. Relationship between macrophage-related mediators and downstream signaling pathways after AKI. When AKI occurs, macrophages migrate to the injured site and activate downstream signal pathways through the production of macrophage-related mediators to regulate the phenotype transformation of macrophages and exert their physiological functions. Macrophage-related mediators include macrophage-derived mediators and macrophage-sensing mediators, which activate signaling pathways related to M1/M2 macrophages, regulate the polarization of macrophages, and affect the development of AKI. AKI, acute kidney injury; MIF, macrophage migration inhibition factor; Lcn-2, lipocalin-2; METs, macrophage extracellular traps; TRIBS, tribbles homolog; MAPK, mitogen-activated protein kinase; PI3K, phosphatidylinositol-3 kinase; Jak, janus kinase; JAK, signal transducer and activator of transcription; NF-κB, nuclear factor-κB.

4. Macrophage-sensing mediators in AKI

Chemokines. Chemokines are a large family of small, secreted proteins that play a fundamental role in the development and dynamic balance of the immune system. Chemokine signals are sent through cell surface G-protein coupled heptahelical chemokine receptors (105). Chemokines play a long-term role in physiological and pathological regulation by inducing macrophage differentiation and polarization (106). C-X-C motif chemokine ligand 14 (CXCL14) is a relatively new CXC type of chemokine, which is constitutively expressed in breast, kidney and other epithelial tissues (107). A previous study indicated that its overexpression inhibits M1 polarization and increases M2 polarization. This suggested that the overexpression of CXCL14 may reduce AKI caused by sepsis by downregulating the production of macrophage-derived cytokines (Fig. 2) (108). Chemokine receptor 5 (CCR5) is a pivotal regulator of the inflammatory cascade response of macrophages in the kidney, and its deficiency contributes to the activation of M2 macrophages (Fig. 2; Table I) (109). Therefore, blocking CCR5 may be helpful in the treatment of I/R-AKI. It has been observed that the deficiency of C-C motif CCR2 can prevent the migration of Ly6C+ macrophages from the bone marrow to the injured site, thus reducing ischemic-AKI in mice (110). In the activation of the renin-angiotensin system, C-C motif chemokine ligand 5 (CCL5) paradoxically limits the accumulation of macrophages in the injured kidney by inhibiting the pro-inflammatory effect of CCL2 (111).

Extracellular matrix proteins. Periostin is a type of cellular-matrix protein of 90 kDa in size, which is highly expressed in bone and tooth tissues (112). As a recently identified biomarker of renal disease, periostin is mainly associated with CKD (113). However, Kormann et al (114) demonstrated that periostin can increase the production of M2 macrophages in the stage of AKI repair, as well as assist the repair of RTECs by promoting the proliferation of macrophages and the secretion of regenerating factors in the kidney (Table I).

Biglycan is a small proteoglycan, abundant in leucine, which acts as a danger signal derived from the extracellular matrix in a soluble form, and it is a high-affinity ligand of CD14 in macrophages (115). The lack of CD14 prevents biglycan-mediated cytokine expression, macrophage recruitment and polarization to M1 macrophages. It also leads to a decrease in the activation of the biglycan-TLR2/4 signaling pathway, thus improving renal function (Figs. 2 and 3) (116). Poluzzi et al (117) showed that CD44 is a novel biglycan signal coreceptor, and its interaction with biglycan is necessary for TLR4/CD44-dependent autophagy in macrophages. Interfering with the interaction between biglycan and specific TLR coreceptors may constitute a novel therapeutic intervention to reduce renal inflammation and injury. Specifically, the role of biglycan in inflammation exceeds its function as a typical danger signal, and it is the first ligand, among numerous types of DAMPs, that has been reported to promote the polarization of M1 and M2 macrophages simultaneously through the transduction of different coreceptor signals (118) (Table I). Biglycan binds to CD44 to promote tissue inflammation, while it binds to CD44 to induce autophagy in M1 macrophages and then promote tissue remodeling (119).
Table I. Macrophage-derived and -sensing mediators in AKI.

### A. Macrophage-derived mediators in AKI

| Mediators | Injury type | Species          | Major findings                                                                 | (Refs.) |
|-----------|-------------|------------------|---------------------------------------------------------------------------------|---------|
| MIF       | APN-AKI     | Human            | A potential biomarker of AKI in patients with APN                               | (74)    |
|           | I/R-AKI     | Human/mouse      | Restoring intracellular glutathione and reducing lipid peroxidation              | (76)    |
|           | RI-AKI      | Mouse            | Regulation of oxidative stress and the long acting of MIF                       | (78)    |
|           | Cisplatin-AKI | Mouse          | Mediating AKI via a CD74-NF-κB dependent mechanism                              | (79)    |
| CD163     | RI-AKI      | Human/mouse      | Magnetic resonance imaging probes targeting macrophage CD163                   | (85)    |
| Lcn-2     | CLP-AKI     | Mouse            | Its iron-load defines the biological function of Lcn-2 in CLP-induced kidney injury | (92) |
| METs      | RI-AKI      | Human/mouse      | Acting as sensors of myoglobin-derived heme in RI-AKI                           | (97)    |
| Trib1     | IR-AKI      | Mouse            | Regulating the proliferation of renal tubular cells by affecting macrophage polarization | (104)  |

### B. Macrophage-sensing mediators in AKI

| Mediators | Injury type | Species  | Major findings                                                                 | (Refs.) |
|-----------|-------------|----------|---------------------------------------------------------------------------------|---------|
| CXCL14    | Sepsis-AKI  | Mouse    | It is overexpressed by downregulating the production of macrophage-derived cytokines | (108)  |
| CCR5      | I/R-AKI     | Mouse    | Its deficiency contributes to the activation of M2 macrophages                  | (109)  |
| CCR2      | I/R-AKI     | Mouse    | Its deficiency prevents the migration of Ly6C+ macrophages from the bone marrow to the site of injury | (113) |
| Periostin | I/R-AKI     | Mouse    | Driving the proliferation of M2 macrophages in the kidney and the secretion of its pro-regeneration factors | (114) |
| Biglycan  | I/R-AKI     | Mouse    | Combining with CD14 to promote tissue inflammation; combining with CD44 to induce autophagy of M1 macrophages and then promote tissue remodeling | (118) |
| EVs + IL-10| I/R-AKI    | Mouse    | Driving M2 macrophage polarization by targeting macrophages in the tubulointerstitium | (125) |
| Exosome (miR-19b-3p) | LPS-AKI | Mouse | Mediating the interaction between damaged tubular epithelial cells and macrophages, leading to the activation of M1 macrophages | (130) |
| Exosome (miR-23a) | I/R-AKI | Mouse | HIF-1α-dependent release of miR-23a-enriched exosomes from hypoxic tubular epithelial cells activates macrophages to promote tubulointerstitial inflammation | (131) |

MIF, macrophage migration inhibitory factor; METs, macrophage extracellular traps; AKI, acute kidney injury; LPS, lipopolysaccharide; I/R-AKI, ischemia/reperfusion-induced AKI; RI-AKI, rhabdomyolysis-induced AKI; APN, acute pyelonephritis; I/R-AKI, ischemia/reperfusion-induced AKI; CLP, cecal ligation and puncture; Lcn-2, lipocalin-2; Trib1, tribbles homolog 1; CXCL14, C-X-C motif chemokine ligand 14; CCR5, chemokine receptor 5; EVs, extracellular vesicles; IL-, interleukin; miR, microRNA; NF-κB, nuclear factor-κB; HIF-1α, hypoxia-inducible factor 1-α.
Extracellular vesicles (EVs) refer to the membrane structures released by all types of cells through different biogenic pathways (120). EVs are intercellular messengers that are involved in a wide range of physiological and pathological processes (121). EVs have the advantages of exhibiting stable physical and chemical properties (122). Therefore, EVs have been used as natural carriers in drug delivery systems in recent years (123). It was previously shown that macrophage-derived EVs have a pro-inflammatory effect (124). By contrast, Tang et al (125) demonstrated that macrophages secrete IL-10+ EVs under dexamethasone stimulation, which can promote the transformation of macrophages into the M2 phenotype (Fig. 2; Table I).

Exosomes are nanoscale EVs that play a key role in intercellular communication and signal transduction. They also play a pivotal role in the processes of inflammation and immune response (126). In recent years, a growing body of evidence has found that exosomes participate in the pathogenesis of renal disease (127,128). Among them, exosomal microRNA (miR)-19b-3p may be a promising therapeutic target for renal disease (129). Tubulointerstitial inflammation is an important pathological feature of AKI. Lv et al (130) found that exosomal miR-19b-3p mediates the interaction between injured RTECs and macrophages, which leads to the activation of M1 macrophages and indicates that the exosome/miR-19b-3p/suppressor of the cytokine signaling axis plays a pivotal role in the development of renal tubulointerstitial inflammation (Fig. 2; Table I). Furthermore, previous studies have demonstrated that the release of hypoxia-inducible factor-1α-dependent miR-23a-enriched exosomes from hypoxic TEcs can activate macrophages and promote tubulointerstitial inflammation (131) (Table I). In addition, blocking the exosome-mediated transfer of miR-23a between RTECs and macrophages may be an innovative method for enhancing renal tubulointerstitial inflammation. In summary, exosomes are involved in adjusting the routine function of the kidney, as well as in promoting and inhibiting various pathophysiological reactions (121).

5. Conclusions

AKI may be caused by a variety of factors and injuries, with a high incidence among critically ill patients (132). When AKI occurs, macrophages, as one of the most significant types of immune cells, are recruited to the injury site to perform their physiological functions. M1 macrophages can aggravate the inflammatory response in order to eliminate potential pathogens. However, excessive inflammatory response aggravates cell and tissue damage. M2 macrophages promote immune suppression and tissue regeneration (28,133). Therefore, the application of M2 macrophages and macrophage-modulating agents is a current research hotspot in the treatment of AKI (11,23). It was previously demonstrated that M2 macrophages can cause the transition from AKI to CKD, which increases the risk of CKD among AKI survivors (34). Recent studies on the role of macrophages in the pathogenesis of AKI suggest the complication and diversity of macrophage activation and the functional status after renal injury (134,135). The multifaceted role of macrophages in AKI is mainly mediated by PI3K, JAK/STAT, RA, NF-κB, MAPK and other signaling pathways (Fig. 1), which may regulate macrophage polarization or oxidative stress (42,44,56,59,68). Among them, the RA signaling pathway is considered to be the current research hotspot, because it not only has an immunosuppressive effect, but also participates in the inflammatory response. Elucidating the mechanism of the RA signaling pathway in AKI and its association with macrophages has great clinical application prospects (136). Macrophage-derived and -sensing mediators such as MIF, CD163, Lcn-2, METs, TRIBM, and biglycan (Fig. 2; Table I) also play an essential role in AKI. Fig. 3 shows the association between macrophage-associated mediators and downstream signaling pathways after AKI. However, the signaling pathway that macrophage mediators participate in may be a complex network, and further research is needed to verify whether there is interaction between different pathways. A thorough understanding of the biological role of macrophages in the process of injury and repair is a necessary condition for understanding the limitations and further applicability of macrophages in therapy. Therefore, future studies should elucidate the mechanism and timing of macrophage polarization, as well as the precise regulatory mechanisms of macrophages in the occurrence and development of AKI, which will contribute to the understanding and identification of novel therapeutic targets for AKI.

Acknowledgements

Not applicable.

Funding

This research was supported by grants from The Open Fund of State Key Laboratory of Medicinal Chemical Biology (Nankai University; grant no. 2020010) and The Tianjin University ‘Double first class’ construction talent start-up fund.

Availability of data and materials

Not applicable.

Authors’ contributions

NL and JC conceived and designed the review, researched the literature and wrote the manuscript. PW contributed to literature collection and figure preparation. SH, HP and YG designed the study, critically revised and supervised the manuscript. Data authentication is not applicable. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.
References

1. Messerer DAC, Halbgauer R, Nilsson B, Ravenstädt H, Radermacher P and Huber-Lang M: Immunopathophysiology of trauma-related acute kidney injury. Nat Rev Nephrol 17: 91‑111, 2021.

2. Eenepoeter J, Davis RP, Barbas AS, Kwan J and Lee J: Immunothrombotic activity of damage-associated molecular patterns and extracellular vesicles in secondary organ failure induced by trauma and sterile insults. Front Immunol 9: 190, 2018.

3. Wynn TA, Chawla A and Pollard JW: Macrophage biology in development, homeostasis and disease. Nature 496: 445‑455, 2013.

4. Ginhoux F and Guilliams M: Tissue‑resident macrophage ontogeny and homeostasis. Immunity 44: 439‑449, 2016.

5. Cohorts of Patients, Am J Kidney Dis 68: S64‑S76, 2016.

6. Wynn TA and Vannella KM: Macrophages in tissue repair, regeneration, and fibrosis. Immunity 44: 450‑462, 2016.

7. Vannella KM and Wynn TA: Mechanisms of organ injury and repair by macrophages. Annu Rev Physiol 79: 593‑617, 2017.

8. Stein M, Keshav S, Harris N and Gordon S: Interleukin‑4 potently enhances murine macrophage mannose receptor activity: A marker of alternative immunologic macrophage activation. J Exp Med 176: 287‑292, 1992.

9. Chen T, Cao Q, Wang Y and Harris DCH: M2 macrophages in kidney disease: Biology, therapies, and perspectives. Kidney Int 95: 760‑773, 2019.

10. Verdeguer F and Aouadi M: Macrophage heterogeneity and energy metabolism. Exp Cell Res 360: 35‑40, 2017.

11. Smigiel KS and Parks WC: Macrophages, wound healing, and fibrosis: Recent insights. Curr Rheumatol Rep 20: 17, 2018.

12. Shapouri‑Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Afshari JT and Esmaeili SA, Mardani F, Seifi B, Mohammadi A, Amano MT, Castoldi A, Andrade‑Oliveira V, Latancia MT, Terra FF, Correa‑Costa M, Breda CNS, Felizardo RJF, Pereira WO, da Silva MB, et al: Quercetin alleviates acute kidney injury and its outcomes. Front Physiol 10: 1016, 2019.

13. Liu H: Glycoprotein non‑metastatic melanoma protein b (Gpnmb) is highly expressed in macrophages of acute injured kidney and promotes M2 macrophages polarization. Cell Immunol 316: 53‑60, 2020.

14. Wu J, Wan X, Zhang H, Li W, Ma M, Pan B, Liang X and Cao C: Retinoic acid attenuates contrast‑induced acute kidney injury in a miniature pig model. Biochem Biophys Res Commun 512: 1631‑1639, 2019.

15. Huen SC and Cantley LG: Macrophage‑mediated injury and repair after ischemic kidney injury. Pediatr Nephrol 30: 199‑209, 2015.

16. Wang SC and Cantley LG: Macrophages in renal injury and repair. Annu Rev Physiol 79: 449‑469, 2017.

17. Huen SC and Cantley LG: Macrophages in acute kidney injury. Nat Rev Nephrol 11: 98‑101, 2015.

18. Yang C and Zhu T: Erythropoietin protects against rhabdomyolysis‑induced acute kidney injury by modulating macrophage polarization. Cell Death Dis 8: e2725, 2017.

19. Zhao L, Zhuo H, Ouyang H, Liu Y, Yuan F, Sun L, Liu F and Liu H: Glycoprotein‑non‑metastatic melanoma protein b (Gpnmb) is highly expressed in macrophages of acute injured kidney and promotes M2 macrophages polarization. Cell Immunol 316: 53‑60, 2020.
Erythropoietin ameliorates lung injury by inhibiting Mincle/Syk/NF-κB signaling maintain
duced macrophage inflammation. Phytother Res 34: 139-152, 2020.

Tang RZ, Liu J, Zhang YY, Wang HL, Li JC, Liu YH, Zhong X, Zhang YW, Yan Y, Lan HY and Wang L: Curcumin relieved cisplatin-induced kidney inflammation through inhibiting Mincle-maintained MI macrophage phenotype. Phytomedicine 52: 284-294, 2019.

Hui WC, Ruan LC, Tan C, Liu Z, Dan W, Jun-Ming F and Li W: Aastragalus propinquus Schischkin and Panax notoginseng (A&P) compound relieved cisplatin-induced acute kidney injury through inhibiting the mincle maintained macrophage inflammation. J Ethnopharmacol 252: 112637, 2020.

Zhou J, Bai Y, Jiang Y, Tanun P, Feng Y, Huang R and Fu P: Immunomodulatory role of recombinant human erythropoietin in acute kidney injury induced by crush syndrome via inhibition of the TLR4/NF-κB signaling pathway in macrophages. Immunopharmacol Immunotoxicol 42: 37-47, 2020.

Xu P, Shen F, Yu B, Xu X, Ge R, Cheng X, Chen Q, Bian J, Li Z and Yang W: NOD-like receptors (NLRs) as potential therapeutic targets for autoimmune diseases and myeloproliferative disorders. Eur J Med Chem 192: 112155, 2020.

Boussoi E and Montazeri Aliabadi H: ‘Do We Know Jack’ About JAK? A closer Look at JAK/STAT signaling pathway. Front Pharmacol 10: 66, 2019.

Banerjee J, Biehl A, Gadina M, Hasni S and Schwartz DM: JAK-STAT signaling as a target for inflammatory and autoimmune diseases: Current and future prospects. Drugs 77: 521-546, 2017.

Zhu M, Wang L, Yang J, Xie K, Zhu M, Liu S, Xu C, Wang J, Gu L, Ni Z, et al: Erythropoietin ameliorates lung injury by accelerating pulmonary endothelium cell proliferation via janus kinase-signal transducer and activator of transcription 3 pathway after kidney ischemia and reperfusion injury. Transplant Proc 51: 972-978, 2019.

Zhang MZ, Wang X, Wang Y, Niu A, Wang S, Zou C and Harris RC: IL-4/IL-13-mediated polarization of renal macrophages/dendritic cells to an M2a phenotype is essential for recovery from acute kidney injury. Kidney Int 91: 375-386, 2017.

van der Linden MJC, Gaspar P, Boot R, Aerts JMFG and van der Velden M: 'Do We Know Jack' About JAK? A closer Look at JAK/STAT signaling pathway. Front Pharmacol 10: 66, 2019.

Li B, Liu C, Tang C, Dong X, Xue L, Su G, Zhang W and Jin Y: Aquaporin-1 attenuates macrophage-mediated inflammatory responses by inhibiting p38 mitogen-activated protein kinase activation in lipopolysaccharide-induced acute kidney injury. Inflamm Res 68: 1035-1047, 2019.

Conserva MR, Anelli L, Zagaria A, Specchia G and Albano F: The pleiotropism of retinoic acid/retinoidic acid receptors signaling: From vitamin A metabolism to gene rearrangements in acute promyelocytic leukemia. Int J Mol Sci 20: 2921, 2019.

Cunningham TJ and Duester G: Mechanisms of retinoic acid signalling and its roles in organ and limb development. Nat Rev Mol Cell Biol 18: 110-123, 2017.

Ghyselinck NB and Duester G: Retinoic acid signaling pathways. Development 146: dev167502, 2019.
86. Ribero-Navarro A, Carril M, Padro D, Guerrero-Hue M, Tarín C, Samaniego R, Cannata P, Cano A, Villalobos JM, Sevillano AM, et al: CD163-Macrophages are involved in rheumatoid induced kidney injury and may be detected by MRI with targeted gold-coated iron oxide nanoparticles. Theranostics 6: 896-914, 2016.

87. Li D, Yan Sun W, Fu B, Xu A and Wang Y: Lipocalin-2-The myth of its expression and function. Basic Clin Pharmacol Toxicol 127: 146-151, 2020.

88. Rahim R, Abd-Alla A, Khand E, Ahmadzadeh E, Jahanian-Najafabadi A and Roudkenar MH: Implication and role of neutrophil gelatinase-associated lipocalin in cancer: Lipocalin-2 as a potential novel emerging therapeutic target for a variety of cancer types. Mol Reprod Dev 87: 127-234, 2020.

89. Santiago-Sánchez GS, Pita-Grisanti V, Quiñones-Díaz B, Gumper K, Cruz-Monserrate Z and Vivas-Mejía PE: Biological functions and therapeutic potential of lipocalin 2 in cancer. Int J Mol Sci 21: 4565, 2020.

90. Desanti De Oliveira B, Xu K, Shen TH, Callahan M, Kiryluk K, D'Agati VD, Tatonetti NP, Barasch J and Devarajan P: Molecular nephrology: Types of acute tubular injury. Nat Rev Nephrol 15: 599-612, 2019.

91. Urbschat A, Thiemens AK, Mertens C, Rehwald C, Meier JK, Baer FC and Jung M: Macrophage-secreted Lipocalin-2 promotes resolution of injured murine renal tubular epithelial cells. Int J Mol Sci 21: 2038, 2020.

92. Mertens C, Kuchler L, Sola A, Guiteras R, Grein S, Brüne B, von Knecht E and Jung M: Macrophage-derived iron-bound lipocalin-2 correlates with renal recovery markers following ischemia-reperfusion injury. Kidney Int 91: 78-27, 2019.

93. Brinkmann V, Reichard U, Gosheim C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y and Zychlinsky A: Neutrophil extracellular traps kill bacteria. Science 303: 1532-1535, 2004.

94. Döster RS, Rogers LM, Gaddy JA and Aronoff DM: Macrophage extracellular traps: A scoping review. J Innate Immun 10: 3-13, 2018.

95. Nakazawa D, Marschner JA, Platen L and Anders HJ: Extracellular traps kill bacteria. Science 303: 1532-1535, 2004.

96. Weiss DS, Weinrauch Y and Zychlinsky A: Neutrophil extracellular traps in kidney disease. Kidney Int 94: 1087-1098, 2018.

97. Hauri D: Macrophages and platelets join forces to release kidney-damaging DNA traps. Nat Med 24: 128-129, 2018.

98. Okubo K, Kurosawa M, Kamiya M, Urano Y, Suzuki A, Yamamoto K, Hase K, Homma K, Sasaki I, Miyachiu H, et al: Macrophage extracellular trap formation promoted by platelet activation is a key mediator of rhabdomyolysis-induced acute kidney injury. PLoS One 15: e023238, 2020.

99. Lichtman A: The kidney gets caught in a macrophage trap. Sci Immunol 3: eaat3745, 2018.

100. Satoh T, Kidoya Y, Naito H, Yamamoto M, Takemura N, Nakagawa K, Yoshikawa T, Murakami N, Takaku T, Oda K: Critical role of Trib1 in differentiation of tissue-injured adult murine heart. J Clin Invest 126: 2151-2166, 2016.

101. Arndt L, Dokas J, Gerick C, Kutscher CE, Müller S, Jeromin F, Wollmann J, Thiery J and Burkhardt R: Tribbles homolog 1 deficiency modulates macrophage polarization to drive repair after AKI. J Am Soc Nephrol 31: 7527-7537, 2020.

102. Arndt L, Dokas J, Gericke M, Kutzner CE, Müller S, Jeromin F, Wollmann J, Thiery J and Burkhardt R: Tribbles homolog 1 deficiency modulates macrophage polarization to drive repair after AKI. J Am Soc Nephrol 31: 7527-7537, 2020.

103. Arndt L, Dokas J, Gericke M, Kutzner CE, Müller S, Jeromin F, Wollmann J, Thiery J and Burkhardt R: Tribbles homolog 1 deficiency modulates macrophage polarization to drive repair after AKI. J Am Soc Nephrol 31: 7527-7537, 2020.

104. Roedig H, Nastave MV, Weygreeca M and Schaefebra L: Breaking down chronic inflammatory diseases: The role of biglycan in promoting a switch between inflammation and autoagy. FEBS J 286: 2965-2979, 2019.

105. Roedig H, Nastave MV, Frey H, Moreth K, Zeng-Brouers J, Poluzzi C, Hisieh LT, Brands C, Fulda S, Weygreca M and Schaefera L: Biglycan is a new high-affinity ligand for CD14 in macrophages. Matrix Biol 77: 4-22, 2020.

106. Roedig H, Nastave MV, Zeng-Brouers J, Roedig H, Hisieh LT, Michaels JB, Buhl EM, Rezende F, Manavski Y, Bleich A, et al: Biglycan evokes autophagy in macrophages via a novel CD44/Toll-like receptor 4 signaling axis in ischemia/reperfusion injury. Kidney Int 95: 540-562, 2019.

107. Meissner M, Viechmann SF and Kunts C: DAMPening sterile inflammation of the kidney. Kidney Int 95: 489-491, 2019.

108. Roedig H, Damiescu R, Zeng-Brouers J, Kutiia I, Trebicka J, Meissner M, Viechmann SF and Kurts C: DAMPening sterile inflammation of the kidney. Kidney Int 95: 489-491, 2019.

109. Roedig H, Damiescu R, Zeng-Brouers J, Kutiia I, Trebicka J, Meissner M, Viechmann SF and Kurts C: DAMPening sterile inflammation of the kidney. Kidney Int 95: 489-491, 2019.

110. Roedig H, Damiescu R, Zeng-Brouers J, Kutiia I, Trebicka J, Meissner M, Viechmann SF and Kurts C: DAMPening sterile inflammation of the kidney. Kidney Int 95: 489-491, 2019.

111. Roedig H, Damiescu R, Zeng-Brouers J, Kutiia I, Trebicka J, Meissner M, Viechmann SF and Kurts C: DAMPening sterile inflammation of the kidney. Kidney Int 95: 489-491, 2019.

112. Roedig H, Damiescu R, Zeng-Brouers J, Kutiia I, Trebicka J, Meissner M, Viechmann SF and Kurts C: DAMPening sterile inflammation of the kidney. Kidney Int 95: 489-491, 2019.
130. Lv LL, Feng Y, Wu M, Wang B, Li ZL, Zhong X, Wu WJ, Chen J, Ni HF, Tang TT, et al: Exosomal miRNA-19b-3p of tubular epithelial cells promotes M1 macrophage activation in kidney injury. Cell Death Differ 27: 210-226, 2020.

131. Li ZL, Lv LL, Tang TT, Wang B, Feng Y, Zhou LT, Cao JY, Tang RN, Wu M, Liu H, et al: HIF-1α inducing exosomal microRNA-23a expression mediates the cross-talk between tubular epithelial cells and macrophages in tubulointerstitial inflammation. Kidney Int 95: 388-404, 2019.

132. Harrois A, Soyer B, Gauss T, Hamada S, Raux M and Duranteau J: Prevalence and risk factors for acute kidney injury among trauma patients: A multicenter cohort study. Crit Care 22: 344, 2018.

133. Zuk A and Bonventre JV: Acute kidney injury. Annu Rev Med 67: 293-307, 2016.

134. Wen Y and Crowley SD: The varying roles of macrophages in kidney injury and repair. Curr Opin Nephrol Hypertens 29: 286-292, 2020.

135. Tang PM, Nikolic-Paterson DJ and Lan HY: Macrophages: Versatile players in renal inflammation and fibrosis. Nat Rev Nephrol 15: 144-158, 2019.

136. Poeck H, Bscheider M, Gross O, Finger K, Roth S, Rebsamen M, Hannesschlager N, Schlee M, Rothenfusser S, Barchet W, et al: Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 beta production. Nat Immunol 11: 63-69, 2010.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.